Previous 10 | Next 10 |
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since t...
Critically ill patients with multiple myeloma will need to wait a lot longer for an experimental new cancer therapy from Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) than they had expected. The FDA has refused to file a new biologics license application...
Bristol Myers Squibb (NYSE: BMY ) and development partner/licensor bluebird bio (NASDAQ: BLUE ) announce that the former has received a Refusal to File letter from the FDA regarding its marketing application seeking approval of idecabtagene vicleucel (ide-cel) (bb2121) for the treatment of...
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the companies received a Refusal to File letter fro...
bluebird bio, Inc. (BLUE) Q1 2020 Results Earnings Conference Call May 11, 2020 08:00 AM ET Company Participants Ingrid Goldberg – Vice President-Investor Relations, bluebird bio, Inc. Nick Leschly – Chief Bluebird & Director, bluebird bio, Inc. David M. Davidso...
A couple of complex collaboration agreements that Bristol Myers Squibb (NYSE: BMY) inherited from Celgene are about to get a lot simpler. The big pharma is going to buy out its obligations to bluebird bio (NASDAQ: BLUE) in all territories outside of the U.S. for just $200 million. Back ...
The following slide deck was published by bluebird bio, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Cellect Biotechnology (NASDAQ: APOP ) +126% on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...
Bluebird bio ( BLUE -0.1% ) Q1 results : More news on: bluebird bio, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Bristol-Myers Squibb (NYSE: BMY ) and bluebird bio (NASDAQ: BLUE ) have amended their existing co-promotion and co-development agreement related to CAR T immunotherapy bb2121. More news on: Bristol-Myers Squibb Company, bluebird bio, Inc., Healthcare stocks news, Stocks on the move, ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...